BioCentury on BioBusiness,
Table: Celgene's equity deals
Back to the parent article
Monday, November 19, 2012
Despite the lack of a venture arm, since 2007 Celgene
Corp. (NASDAQ:CELG) has provided venture funding to at least eight
companies and done six deals in which it took an equity stake. With
eight of these companies, Celgene received an option to acquire programs or the
company itself. (A) Acquired by Shire plc (LSE:SHP; NASDAQ:SHPG) in
2012; Source: BCIQ: BioCentury Online Intelligence; company press releases
Status at time of deal
develop and commercialize Acceleron's cancer compound ACE-011 and option to
jointly develop and commercialize three undisclosed discovery programs for
cancer and cancer-related
up front, including a $5M equity investment; $510M in milestones for ACE-011,
plus tiered royalties; Celgene will also purchase a minimum of $7M in an IPO;
$437M in milestones for each of the three undisclosed programs
words displayed of
To read this article, you must be an Archives subscriber. Please choose one of the options below.
All contents Copyright © 1993-2013 BioCentury Publications, Inc. ALL RIGHTS RESERVED. All use of this Web Site and its contents is governed by the BioCentury User Agreement
. The contents of this Web Site are protected under U.S. and foreign copyright and intellectual property laws, and no part of this Web Site or its contents may be photocopied, reproduced or retransmitted in any form without the written consent of BioCentury, which may be requested from Reprints/Permissions
. BioCentury®; The Bernstein Report on BioBusiness™; The BioCentury 100™; The Clear Route to ROI™; Because Real Intelligence is Hard to Find™; BCIQ™; and BioPharma's Knowledge Center™; are trademarks of BioCentury Publications, Inc., P.O. Box 1246, San Carlos, CA 94070. SciBX® and SciBX: Science-Business eXchange® are trademarks of Nature America, Inc. that are jointly used by BioCentury Publications, Inc. and Nature America, Inc.
If you are a current subscriber, log in below or in the upper right corner of this
Whether you want an individual subscription or need a global group license, we have the products,
the experience and the customer support that biopharma executives, researchers, investors, service providers,
and industry stakeholders have trusted for nearly two decades.
Let our Subscriber Services team customize the best intelligence package available in the industry to meet your needs.
Free Trial 4 Weeks of Access
Get a 4-week free trial subscription to see the important articles you are missing.
Get 4 Weeks Free
Thanks for purchasing this article.
Please bookmark this url for future reference.
We have also sent you a confirming e-mail with a receipt and this same url for your
close [ X ]